{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T22:16:15Z","timestamp":1759616175248},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.jhep.2005.12.004","type":"journal-article","created":{"date-parts":[[2006,1,20]],"date-time":"2006-01-20T12:41:43Z","timestamp":1137760903000},"page":"507-511","source":"Crossref","is-referenced-by-count":22,"title":["The effect of pegylated interferon-\u03b1 on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection"],"prefix":"10.1016","volume":"44","author":[{"given":"Wilhelmus F.","family":"Leemans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajo J.","family":"Flink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert G.M.","family":"Niesters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solko W.","family":"Schalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"de Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2005.12.004_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jhep.2005.12.004_bib2","first-page":"1059","article-title":"Treatment of lamiduvine-resistant mutant chronic hepatitis B with interferon alpha","volume":"26","author":"Pariente","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2005.12.004_bib3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1368-5031.2004.00011.x","article-title":"Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B","volume":"58","author":"Danalioglu","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jhep.2005.12.004_bib4","first-page":"223","article-title":"Interferon re-treatment for resistance to lamivudine plus interferon treatment","volume":"14","author":"Ersoz","year":"2003","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.jhep.2005.12.004_bib5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s005350200155","article-title":"Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy","volume":"37","author":"Suzuki","year":"2002","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2005.12.004_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.12.004_bib7","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.12.004_bib8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0168-8278(01)00145-3","article-title":"Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial","volume":"35","author":"Barbaro","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.12.004_bib9","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1046\/j.1440-1746.17.s3.23.x","article-title":"Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B","volume":"17","author":"Liaw","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2005.12.004_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","article-title":"Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia hepatitis lamivudine study group","volume":"119","author":"Liaw","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.12.004_bib11","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","article-title":"Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy","volume":"33","author":"Leung","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.12.004_bib12","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1440-1746.2004.03428.x","article-title":"Four years of lamivudine treatment in Chinese patients with chronic hepatitis B","volume":"19","author":"Chang","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2005.12.004_bib13","first-page":"S3","article-title":"EASL international consensus conference on hepatitis B. 13\u201314 September, 2002 Geneva, Switzerland. Consensus statement (long version)","volume":"39","author":"de Franchis","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.12.004_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.12.004_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JCM.37.1.68-73.1999","article-title":"Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep pathobiology group","volume":"37","author":"Heermann","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2005.12.004_bib16","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1128\/JCM.38.8.2897-2901.2000","article-title":"Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays","volume":"38","author":"Pas","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2005.12.004_bib17","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/S0168-8278(03)00327-1","article-title":"The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferon","volume":"39","author":"Cooksley","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.12.004_bib18","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.12.004_bib19","first-page":"660A","article-title":"HBsAg seroconversion in chronic HBV patients treated with pegylated interferon alpha-2b alone or in combination with lamivudine. The role of HBV genotype","volume":"40","author":"Janssen","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.12.004_bib20","first-page":"1425","article-title":"HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C","volume":"36","author":"Wai","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.12.004_bib21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","article-title":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B","volume":"118","author":"Kao","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.12.004_bib22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0168-8278(00)80135-X","article-title":"Hepatitis B genotypes and the response to interferon therapy","volume":"33","author":"Kao","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.12.004_bib23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2002","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2005.12.004_bib24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/gut.2003.032920","article-title":"High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B","volume":"54","author":"Lin","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2005.12.004_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2003.10.050","article-title":"Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus","volume":"126","author":"Perrillo","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.12.004_bib26","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1128\/AAC.46.8.2525-2532.2002","article-title":"Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro","volume":"46","author":"Levine","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2005.12.004_bib27","first-page":"664A","article-title":"Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: results of phase III study ETV-026","volume":"40","author":"Sherman","year":"2004","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827805008226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827805008226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T06:25:17Z","timestamp":1586672717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827805008226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0168827805008226"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2005.12.004","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}